| BIIB |
Report |
Q2 2026 total revenue |
BEAT |
pred ~$2.51B vs. cons $2.47B |
MEDIUM |
| BIIB |
Report |
Q2 2026 non-GAAP diluted EPS |
BEAT |
pred ~$2.48 vs. cons $2.35 |
MEDIUM |
| BIIB |
Report |
Q2 2026 consolidated SYFOVRE and EMPAVELI product revenue |
BEAT |
pred ~$104M vs. cons $100M |
LOW |
| BIIB |
Guide |
FY 2026 total revenue |
LOWER |
guide ~$10.00B vs. cons $10.11B (FY 2026) |
MEDIUM |
| BIIB |
Guide |
FY 2026 non-GAAP diluted EPS |
BETTER |
guide ~$12.00 vs. cons $11.68 (FY 2026) |
LOW |
| BIIB |
Guide |
FY 2027 non-GAAP diluted EPS commentary |
LOWER |
guide ~$16.25 vs. cons $16.54 (FY 2027) |
LOW |
| BIIB |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.8% |
— |
MEDIUM |
| BIIB |
Return |
5-day cumulative residual |
+0.8% (FADE) |
Headline beats and FY 2026 EPS guidance support day 1, but the implied FY 2027 EPS outlook of ~$16.25 versus consensus $16.54 drives estimate cuts as Apellis costs, interest expense and growth investment flow through the out-period model. |
LOW |